pCPA Activity Overview
Status | Total Negotiations | Summary |
---|---|---|
Active Negotiations | 30 | Non-oncology: 16 Oncology: 14 |
Under Consideration for Negotiation | 27 | Non-oncology: 17 Oncology: 10 |
Completed Negotiations | 686 | With Letter of Intent: 589 Without agreement: 97 |
Negotiations That Were Not Pursued | 103 |
pCPA Activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement Letters Issued in the last four weeks
Brand Name | Manufacturer | Indication | Engagement Date |
---|---|---|---|
Epkinly (pTAP negotiation) | AbbVie Corporation | For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or | |
To be confirmed | Sandoz Canada Inc. | Multiple Indications | |
Wyost | Sandoz Canada Inc. | Multiple Indications | |
Jubbonti | Sandoz Canada Inc. | Multiple indications |